We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 23 Jun 2021
Randox Laboratories (Crumlin, UK) shared a wealth of new products and innovative technologies with the industry at the 2021 edition of MEDLAB Middle East.

Randox has developed a range of new tests for COVID-19 (SARS-CoV-2) targeting genes in line with WHO & CDC recommendations. More...
Utilizing Patented Biochip Technology, with results available from the Vivalytic, Evidence Investigator and Randox Discovery, capable of detecting both SARS-CoV-2 and Sarbecovirus (confirmatory target), to report SARS-CoV-2 positive patient samples. The Vivalytic, Evidence Investigator and Randox Discovery platforms were on display at this year’s MEDLAB Middle East.

Randox also showcased its new benchtop lab - Randox Discovery - an exciting and unique analyzer consolidating molecular and immunoassay workflows onto one compact benchtop platform. The COVID-19 diagnostic analyzer is the first to combine sample preparation techniques including extraction, PCR & Biochip Technology. Simple and easy to use, the intuitive user-interface guides the operator through the entire testing process. Built with the user and laboratory in mind, a single operator is all that is required to run up to three fully automated discovery platforms increasing operator walkaway time and ensuring rapid turnaround time of three hours to first batch results.

In addition, Randox presented the RX series of clinical chemistry analyzers that offer the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, veterinary and diabetes testing. They guarantee real cost savings through consolidation of routine and specialized tests onto a single platform. The RX series analyzers - RX MISANO, RX MONACO, RX DAYTONA+,

RX IMOLA and RX MODENA - deliver excellence in patient care, offering unrivalled precision with excellent reagent CV ranges, providing laboratories with the upmost reliability, analyser uptime and accuracy of patient results. With their extensive test menu and versatile range of analyzers, the RX series presents the ultimate in performance, functionality and efficiency with testing capabilities to suit all laboratory sizes and types. Renowned for robust hardware and intuitive software, the RX series continues to revolutionize testing in a variety of laboratory types including; Clinical Laboratories, University & Research Institutes, Veterinary Laboratories and Food & Wine Testing Laboratories.

Related Links:
Randox Laboratories


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
All-in-One Molecular System
AIO M160
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.